Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity

被引:33
|
作者
Zhang, Jiu-cheng [1 ,2 ]
Chen, Wei-dong [1 ,2 ]
Alvarez, Jean Bustamante [3 ]
Jia, Kelly [3 ]
Shi, Lei [4 ]
Wang, Qiang [4 ]
Zou, Ning [1 ,2 ]
He, Kai [3 ]
Zhu, Hua [4 ]
机构
[1] Hubei Canc Hosp, Dept Radiat Oncol, Wuhan 430079, Hubei, Peoples R China
[2] Ohio State Univ, Wexner Med Ctr, Dept Internal Med, Columbus, OH 43210 USA
[3] James Canc Hosp, Columbus, OH 43210 USA
[4] Ohio State Univ, Wexner Med Ctr, Davis Heart & Lung Res Inst, Dept Surg, Columbus, OH 43210 USA
关键词
cancer immunotherapy; immune checkpoint inhibitor; CTLA-4; PD-1; PD-L1; cardiac toxicity; myocarditis; REGULATES PD-1 EXPRESSION; INHIBITORY RECEPTOR PD-1; T-LYMPHOCYTE ANTIGEN-4; ADVANCED MELANOMA; B7; FAMILY; CTLA-4; IMMUNOTHERAPY; IPILIMUMAB; NIVOLUMAB; MYOCARDITIS;
D O I
10.1038/s41401-018-0062-2
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The immune checkpoint molecules are emerged in the evolution to protect the host from self-attacks by activated T cells. However, cancer cells, as a strategy to survive and expand, can hijack these molecules and mechanisms to suppress T cell-mediated immune responses. Therefore, an idea of blocking the checkpoint molecules to enhance the anti-tumor activities of the host immune system has been developed and applied to the cancer therapy after discovery of the inhibitory T cell co-receptor, cytotoxic T-lymphocyte associated protein 4 (CTLA-4), and further enhanced on the identification of PD-1 and its ligands. Since 2010, several checkpoint inhibitors have been approved by FDA and many more are in clinical trials. In the treatment of advanced cancers, these inhibitors significantly increased response rates and survival benefits. However, accompanied with the striking results, immune-related adverse events (irAEs) that broadly occurred in many organs were observed and reported, some of which were fatal. Herein, we first review the recent progressions in the research of the immune checkpoint molecules and the application of their blocking antibodies in cancer treatment, and then discuss the cardiac toxicity induced by the therapy and the strategy to monitor, manage this adverse event when it occurs.
引用
收藏
页码:1693 / 1698
页数:6
相关论文
共 50 条
  • [1] Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity
    Jiu-cheng Zhang
    Wei-dong Chen
    Jean Bustamante Alvarez
    Kelly Jia
    Lei Shi
    Qiang Wang
    Ning Zou
    Kai He
    Hua Zhu
    [J]. Acta Pharmacologica Sinica, 2018, 39 : 1693 - 1698
  • [2] Immune Checkpoint Blockade in Cancer Therapy
    Postow, Michael A.
    Callahan, Margaret K.
    Wolchok, Jedd D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) : 1974 - U161
  • [3] Immune Checkpoint Blockade in Breast Cancer Therapy
    Bu, Xia
    Yao, Yihui
    Li, Xiaoyu
    [J]. TRANSLATIONAL RESEARCH IN BREAST CANCER: BIOMARKER DIAGNOSIS, TARGETED THERAPIES AND APPROACHES TO PRECISION MEDICINE, 2017, 1026 : 383 - 402
  • [4] Immune checkpoint blockade therapy in cancer and beyond
    Minato, Nagahiro
    [J]. CYTOKINE, 2017, 100 : 23 - 23
  • [5] Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy
    King, G. T.
    Sharma, P.
    Davis, S. L.
    Jimeno, A.
    [J]. DRUGS OF TODAY, 2018, 54 (02) : 103 - 122
  • [6] Immune checkpoint blockade therapy for bladder cancer treatment
    Kim, Jayoung
    [J]. INVESTIGATIVE AND CLINICAL UROLOGY, 2016, 57 : S98 - S105
  • [7] Immune Checkpoint Associated Cardiotoxicity: An Update
    Chauhan, A.
    Mynt, Z.
    Arnold, S.
    Grant, B.
    Anthony, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2147 - S2148
  • [8] Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies
    Byun, David J.
    Wolchok, Jedd D.
    Rosenberg, Lynne M.
    Girotra, Monica
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2017, 13 (04) : 195 - 207
  • [9] Cardiotoxicity Associated with Immune Checkpoint Inhibitors
    Minegishi, Shintaro
    Horita, Nobuyuki
    Ishigami, Tomoaki
    Hibi, Kiyoshi
    [J]. CANCERS, 2023, 15 (22)
  • [10] Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies
    David J. Byun
    Jedd D. Wolchok
    Lynne M. Rosenberg
    Monica Girotra
    [J]. Nature Reviews Endocrinology, 2017, 13 : 195 - 207